Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAMM2: Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma
NCT04527549Phase 2Terminated
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing Arm A (dabrafenib, trametinib, hydroxychloroquine) with Arm B (dabrafenib, trametinib, placebo) (2 arms). Primary endpoint: One-year Progression-free Survival Rate at 1 year. Started Jun 2021; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04527549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527549.